Jamialahamdi Tannaz, Mirhadi Elaheh, Almahmeed Wael, Virani Salim, Eid Ali H, Al-Rasadi Khalid, Salehabadi Sepideh, Sahebkar Amirhossein
Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Obes Surg. 2025 May 26. doi: 10.1007/s11695-025-07848-y.
A significant number of patients encounter weight gain (WG) or inadequate weight loss (IWL) following bariatric surgery for obesity. Recent studies have explored the role of semaglutide in addressing weight management challenges in patients who have inadequate weight loss or weight gain after bariatric surgery. Despite such studies, a systematic review and meta-analysis evaluating the efficacy, safety and tolerability of semaglutide in this specific clinical context remains absent. Therefore, this study was undertaken to address this knowledge gap.
Databases were searched for randomized controlled trials (RCTs), case-control, cohort and observational studies involving use of semaglutide in the intervention arm post-bariatric surgery. Outcome was weight loss post-bariatric surgery.
A total of six studies (300 participants) demonstrated significant weight reduction following semaglutide administration after bariatric surgery (WMD: - 15.730, 95% CI: - 22.140, - 9.320, p < 0.001). This effect remained robust in sensitivity analysis.
The current data encourages the use of semaglutide for managing WG or IWL post-bariatric surgery.
相当数量的肥胖患者在接受减肥手术后出现体重增加（WG）或体重减轻不足（IWL）的情况。最近的研究探讨了司美格鲁肽在解决减肥手术后体重减轻不足或体重增加患者体重管理挑战方面的作用。尽管有这些研究，但仍缺乏一项系统评价和荟萃分析来评估司美格鲁肽在这一特定临床背景下的疗效、安全性和耐受性。因此，本研究旨在填补这一知识空白。
检索数据库，查找涉及在减肥手术后干预组使用司美格鲁肽的随机对照试验（RCT）、病例对照、队列和观察性研究。结局指标为减肥手术后的体重减轻情况。
共有六项研究（300名参与者）表明，减肥手术后给予司美格鲁肽后体重显著减轻（加权均数差：-15.730，95%置信区间：-22.140，-9.320，p<0.001）。在敏感性分析中，这一效果仍然显著。
目前的数据支持使用司美格鲁肽来管理减肥手术后的体重增加或体重减轻不足问题。
